Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
H.C. Wainwright retained its Buy rating on Kazia Therapeutics and affirmed an $18.00 price target after the company released updated Phase 1b data for paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer (TNBC). The small-cap biotech, trading at $7.15 with a market capitalization of $77…
President Donald Trump issued a public ultimatum urging Iran to negotiate a nuclear deal or face a more severe U.S. military response, writing that time is running out and calling for an agreement with "NO NUCLEAR WEAPONS." He said the previous warning led to a strike and warned that the next attack would be "far worse," while also asserting that a…
UBS cut its rating on Swiss property owner Mobimo to sell from neutral, saying the company’s development profits - a key earnings driver - should peak in fiscal 2025 and then decline as high-margin projects complete. The broker raised its 12-month price target to CHF330 from CHF308 after lowering its WACC and modestly raising revenue forecasts, but…
In the first weeks of 2026, numerous U.S. companies across technology, consumer, manufacturing, logistics and financial sectors have announced workforce reductions. The moves are framed as cost-cutting, operational consolidation and resource reallocation toward artificial intelligence and cloud initiatives. The rounds of cuts range from several hun…
F5 Networks reported first-quarter fiscal 2026 results that outperformed expectations, prompting an upward revision to full-year guidance while leaving some analysts cautious. The company beat revenue and EPS forecasts, posted strong margins and notable regional and segment gains, yet Needham preserved a Hold rating pending more sustained outperfor…
H.C. Wainwright reaffirmed its Buy rating and $60 price target for Maze Therapeutics (MAZE), citing a potential regulatory shortcut enabled by pediatric extrapolation for APOL1-mediated kidney disease. Multiple analysts have adjusted models and initiated coverage over recent weeks, reflecting heightened optimism ahead of a pivotal Phase 2 HORIZON r…
Evercore ISI raised its price target on Viridian Therapeutics to $45 from $44 while keeping an Outperform rating as the company approaches Phase 3 subcutaneous thyroid eye disease (TED) data expected in Q1 2026. The new target implies roughly 34% upside from the stock's then-current price of $33.54. The research house highlighted the importance of …
H.C. Wainwright raised its price target on Hecla Mining to $36.50 from $16.50 and kept a Buy rating after the miner reported stronger production across silver, gold, lead and zinc. The firm pointed to robust silver market demand and operational improvements, while market metrics show the stock trading at elevated multiples.
H.C. Wainwright has kept a Buy rating and a $16.00 price target on Aclaris Therapeutics (ACRS) after the company reported encouraging preclinical outcomes for ATI-2138 in a severe alopecia areata mouse model. The study, conducted by Dr. Angela Christiano at Columbia University, showed rapid and near-complete hair regrowth that outperformed Pfizer’s…
H.C. Wainwright increased its price target on Intellia Therapeutics to $25.00 from $15.00 and kept a Buy rating after the clinical hold on the MAGNITUDE-2 trial was lifted. Regulators allowed the Phase 3 study for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) to resume under amended safeguards and an increased target enrollmen…
H.C. Wainwright has maintained a Buy rating and a $185.00 price target on Belite Bio (NASDAQ: BLTE) following the company’s announcement that the Phase 2/3 portion of the DRAGON II trial has completed enrollment of 60 adolescent subjects. The stock trades near its 52-week high after a strong year. Several other brokerages have initiated or reiterat…
Wedbush has reaffirmed an Outperform rating and a $350 price target on Apple ahead of the company’s fiscal first-quarter 2026 earnings report, arguing that recent holiday results and strategic initiatives could outpace current market expectations. The stock trades above InvestingPro’s Fair Value, and several other brokerages have issued divergent p…
H.C. Wainwright has reaffirmed a Buy rating and a $24.00 price target on Inventiva SA (NASDAQ: IVA) following a poster presentation at the Keystone Obesity Conference. The investment firm highlighted a unimolecular quintuple agonist described by researchers from Helmholtz Munich as supportive of Inventiva’s therapeutic approach combining GLP-1R and…
GLDD is trading near $15.21 with bullish momentum, improving earnings power, and strong backlog visibility. With the stock sitting above key moving averages and just below its 52-week high, this looks like a clean mid-term breakout setup where fundamentals and technicals actually agree. The trade: look for a pullback entry near support, target a re…
Canaccord Genuity has reiterated a Buy rating on Stride Inc. (LRN) and kept a $125.00 price target following the company’s fiscal second-quarter results. The target implies roughly 73% upside versus the current share price of $72.43. Stride delivered revenue and enrollment broadly in line with expectations while reporting profitability above consen…
UBS downgraded Nucor from Buy to Neutral while increasing its price target to $183 from $168. The decision reflects concerns that lower-cost steel imports from Southeast Asia and Brazil became economically viable in mid-October and that additional supply could hit U.S. markets starting in February. The move comes after Nucor outperformed peers sinc…
Barclays has begun coverage of Vertex Pharmaceuticals (NASDAQ: VRTX) with an Overweight rating and a $606 price target, highlighting the companys renal franchise, expected trial readouts in 2026, and potential revenue acceleration for the new acute pain therapy Journavx. Multiple other brokerages have recently raised ratings and price targets for …
UBS raised its target on Seagate Technology to $385 from $335 while retaining a Neutral rating, citing strong execution, expanding gross margins and progress on HAMR technology. The firm also increased EPS forecasts for fiscal 2026-2028 but warned that the stock may be pricing in a prolonged uptrend. Seagate recently posted better-than-expected fis…
Barclays initiated coverage of PTC Therapeutics (NASDAQ: PTCT) with an Overweight rating and a $119 price target, citing the commercial opportunity for the company’s phenylketonuria therapy Sephience and potential upside from Huntington’s disease programs. The target implies meaningful upside from the stock's recent trading level, and Barclays note…
Former U.S. President Donald Trump announced on his Truth Social platform that a "massive Armada" led by the aircraft carrier Abraham Lincoln is en route to Iran. He described the force as moving "quickly, with great power, enthusiasm, and purpose," warned of a rapid and potentially violent response if necessary, and urged Iran to "Come to the Tabl…
Morgan Stanley upgraded Hensoldt AG to an "equal-weight" rating from "underweight" and nudged its price target up to €82 from €78 following a roughly 23% decline from the stock's October high. The bank said consensus estimates have been reset after the company's capital markets day and adjusted its forecasts to reflect new guidance, changing free c…
Public Policy Holding Company priced its initial public offering at $12.25 per share, generating roughly $50.8 million in gross proceeds before expenses. The transaction includes both new shares and secondary shares sold by existing stockholders, and underwriters hold a 30-day option to purchase additional shares. Trading began on the Nasdaq Global…
PaleBlueDot AI secured $150 million in a Series B round led by B Capital, pushing its valuation above $1 billion. The Palo Alto-based neocloud company will deploy the funding to acquire Nvidia GPUs and related infrastructure, hire personnel to grow partnerships, and expand both its marketplace for spare GPU capacity and dedicated enterprise GPU clu…
BTIG reduced its price target for Roblox Corp. to $141 from $174 while maintaining a Buy rating ahead of the company’s fourth-quarter results due on February 5. The firm modestly raised bookings estimates for late-2025 and 2026, pointing to a split between weaker concurrent-user metrics and relatively stronger payer and monetization signals. Other …
Barclays initiated coverage of BridgeBio Pharma (BBIO) with an Overweight rating and an $80.00 price target, noting the company’s diversified late-stage portfolio and potential to scale. The move follows strong Attruby sales and preliminary revenue figures for 2025 and coincides with BridgeBio’s $550 million convertible note offering due 2033.
